Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Soligenix Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease
Sept. 7, 2012
Soligenix, a development stage biopharmaceutical company, announced that the FDA has completed its review and cleared the IND application for SGX203 (oral beclomethasone 17,21-dipropionate) for the induction treatment of pediatric Crohn’s disease.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing